Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec)
## Overview
Durveqtix is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a functional copy of the *F9* gene to hepatocytes. It enables the liver to produce functional Factor IX (FIX) protein, potentially providing long-term correction of Hemophilia B.
## Primary Indications
Treatment of adults with moderate to severe Hemophilia B (congenital Factor IX deficiency) who are currently using Factor IX prophylaxis therapy or have a history of life-threatening hemorrhage or repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is **5 x 10^11 vector genomes (vg) per kilogram** of body weight, administered as a single, one-time intravenous infusion.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use in pediatric populations is not currently recommended.
## Dose Adjustments
* **Hepatic Impairment:** Patients with pre-existing significant hepatic impairment (e.g., cirrhosis, advanced fibrosis) may not be suitable candidates; clinical efficacy is dependent on functional hepatocyte transduction.
* **Renal Impairment:** No specific dose adjustments are required.
## Contraindications
* Known hypersensitivity to fidanacogene elaparvovec or any of its components.
* Active, uncontrolled infection (acute or chronic).
* Advanced hepatic disease or portal hypertension.
## Adverse Effects
* **Elevated Liver Enzymes:** Common increases in ALT/AST; requires corticosteroid management.
* **Infusion-Related Reactions:** Pyrexia, nausea, fatigue, headache, and tachycardia.
* **Immunogenicity:** Development of anti-AAV antibodies may preclude repeat dosing and affect future gene therapy candidacy.
## Key Drug Interactions
* **Corticosteroids:** Concomitant use (e.g., prednisone or prednisolone) is mandatory for prophylactic management of immune-mediated hepatitis.
* **Hepatotoxic Agents:** Avoid or use with extreme caution other agents that cause liver enzyme elevation, as they may complicate the monitoring of liver safety post-infusion.
## Monitoring
* **Liver Function Tests (ALT/AST):** Weekly for at least the first 3 months post-infusion; continue as dictated by clinical status and corticosteroid tapering schedule.
* **Factor IX Activity Levels:** Monitor frequently until steady state is reached to assess therapeutic response.
* **Coagulation Profile:** Monitor for signs of potential thrombus formation or sub-therapeutic factor levels during the transition from prophylaxis.
## Clinical Pearls
* **Liver Enzyme Management:** If ALT levels rise, promptly start or escalate prophylactic corticosteroids. Failure to manage transaminitis may result in the loss of therapeutic expression of the transgene.
* **Prophylaxis Transition:** Patients should not immediately discontinue factor prophylaxis post-infusion; clinical tapering should follow institutional protocols based on patient-specific FIX activity levels.
* **Antibody Screening:** Prior to infusion, patients must be screened for pre-existing neutralizing antibodies to the AAV variant; presence of these antibodies may lead to treatment failure.
* **Irreversibility:** As a one-time gene therapy, patients must be counseled that this is a permanent intervention; patients may not be eligible for other AAV-based gene therapies in the future.
***
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Clinical protocols and prescribing information regarding gene therapies evolve rapidly. Always consult the most recent FDA-approved Prescribing Information (Package Insert) and your institution’s clinical pharmacy guidelines before prescribing or administering this medication.
